ODN 2088

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.

ODN 2088 is a TLR7/8/9 antagonist. The sequence can form G-Tetrad structures.

Select a size:
Specifications for ODN 2088
Overview

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.

ODN 2088 is a TLR7/8/9 antagonist. The sequence can form G-Tetrad structures.

Detailed product information
Background information

TLR7, TLR8 and TLR9 are prominent members of the Toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns recognizing nucleic acids 3. Activation of these TLRs can be inhibited by short single-stranded synthetical oligodeoxyribonucleotides (ODNs) 4,6. Several classes of and motifs for inhibitory ODN have been identified 1,6,7.

Applications

TLR7/8/9 Antagonists can be used to inhibit TLR7/8/9 mediated cellular responses, such as activation of immune cells, human PBMCs, murine splenocytes or isolated immune cells (e.g., B cells and pDCs).

TLR7/8/9 Antagonists can be used to inhibit signaling in TLR7/8/9-

expressing recombinant cell lines.

ODN 2088 is a widely used inhibitory ODN inhibiting TLR7, TLR8 and TLR9 1,2,4-7. ODN 2088 forms tertiary structures (G tetrads).

Citations for ODN 2088
Publications
  1. Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11 (5): 373-384
  2. Hackstein H. et al. (2011) The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cell. Immunol. 271: 401-412
  3. Lenert, P. et al. (2001) CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 11: 247-256
  4. Jurk, M. et al. (2006) Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur. J. Immunol. 36: 1815-1826
  5. Lenert, P. S. (2010) Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010: 986596
  6. Stunz, L. L. et al. (2002) Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32: 1212-1220
  7. Krieg, A. M. et al. (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U.S.A. 95: 12631-12636

You have previously chosen International as your location.
What do you want to do?